Skip to main content
Equibles
CADL logo

CADL · Candel Therapeutics, Inc.

Track CADL — free

Use CADL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.76 -0.21 (-1.62%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$1.01B
Shares
76.52M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.97 Open$13.21 Day$12.73–13.28 52W close$4.42–13.75 Avg vol 30d1.2M Short int12.5M · 16.3% float · 10.6d Short vol49% Last earningsMay 20, 2026 DataJul 2021–Sep 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Feb 23, 2028 Est · unconfirmed · in 77 wks
Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$125,000
Trailing 12 months
Net income (TTM)
−$88.53M
Trailing 12 months
Revenue growth YoY
+0.0%
Year over year
Operating margin
-27,777.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+44.0%
Year over year · more shares
Price change (1Y)
+154.1%
Trailing year
Short interest
16.3%
Latest settlement · 10.6 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.47
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +76%
above
Price vs 50-day avg +19%
above
RSI (14) 59
neutral
MACD trend Negative
52-week position 92%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +23%
trailing
6-month return +178%
trailing
YTD return +130%
this year
Relative strength +161%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $11 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+21% holders QoQ · +40 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.29% of float · ▼ -1.5% MoM · 10.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
139 holders — near 3-yr high, broad support
Squeeze score 75
high risk · 0–100
Fundamentals
Strong
Revenue growth 0%
Y/Y
EPS growth +59%
Y/Y
Free cash flow $-38.9M
Balance sheet $82.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 72%
annualized · 1-yr
Max drawdown −33%
past year
ATR 5.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+76% Bullish
Price vs 50-day avg
+19% Bullish
RSI (14)
59 Neutral
MACD trend
Negative Bearish
52-week position
92% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $11 › 200d $7 — 50d above 200d
Institutional flow Accumulating
+21% holders QoQ · +40 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.29% of float · ▼ -1.5% MoM · 10.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
139 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $13 · 92% Range high $14
vs 200-day avg +76% vs 50-day avg +19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CADL
Candel Therapeutics, Inc.
this stock
$1.01B +129.6% +0.0% — 16.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $141.42B +23.1% +46.2% 32.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.84B +9.3% +20.8% 20.9 2.3%
ARGX
Argenx SE
 $64.44B +25.3% — — 1.9%
CSLLY
Csl Ltd
 $59.96B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
139
% held
66.4%
Net QoQ
+6.9M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
114
View
Short & Settlement
Short Interest Falling
Shares short
12.5M
Days to cover
10.6d
Change
-192.1K sh
View
Short Volume
Short vol %
49%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
95
Value
$1.0K
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
50.0%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$125.0K
Net income (FY)
$-38.2M
EPS diluted
$-0.72
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
15
View
Proposed Sales
Value
$82.0K
Shares
7.0K
Filed
Aug 17, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View

Performance

5D 20D 120D MTD YTD
CADL -5.7% +22.6% +177.7% -0.8% +129.6%
SPY +0.3% +0.6% +16.7% +0.8% +13.4%
vs SPY -5.9% +22.0% +161.0% -1.6% +116.2%
Key facts CIK 1841387 CUSIP 137404109 13F (30d) 109 filings 109 filers Visit website Investor relations